GLP-1 Pharmacokinetics: Drug Level Science & Calculations

Key Takeaways

Half-life determines how long a drug stays in your system - after 5 half-lives, ~97% is eliminated
First-order kinetics means a constant fraction (not amount) of drug is eliminated per unit time
Steady-state is achieved after 4-5 half-lives, where drug input equals elimination
Individual factors like genetics, age, and organ function can vary drug clearance by 5-20 fold
Injected semaglutide (89%) and tirzepatide (80%) have high bioavailability; no figure had been published for retatrutide as of October 2026

The Foundation: What is Pharmacokinetics?

This guide applies pharmacokinetic principles specifically to GLP-1 receptor agonists, specifically semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide, the medications modeled by GLP3 Planner's drug level calculator. While the fundamentals apply to all drugs, the examples, tables, and modeling details focus on these weekly injectable peptides and their unique pharmacokinetic profiles.

Pharmacokinetics (PK) is the quantitative study of drug movement through the body over time. Often summarized as "what the body does to the drug," it encompasses four fundamental processes known as ADME:

Absorption: How the drug enters systemic circulation
Distribution: How the drug spreads throughout body tissues
Metabolism: How the drug is chemically transformed
Elimination: How the drug and its metabolites leave the body

These processes determine drug concentrations at any time point, inform dosing decisions, and explain why the same dose can produce different effects in different people.

Compartmental Models: Simplifying Complexity

One-Compartment Model

The simplest pharmacokinetic model treats the entire body as a single, well-mixed compartment. This model assumes:

Instantaneous and homogeneous drug distribution
Rapid equilibration between blood and tissues (15-30 minutes)
Linear elimination kinetics

Mathematical representation:

C(t) = C₀ × e^(-ke × t)

Where:
C(t) = concentration at time t
C₀ = initial concentration
ke = elimination rate constant (0.693/t½)
t = time elapsed

Best suited for: Hydrophilic drugs confined to extracellular fluid, drugs with small volumes of distribution, and situations where simplified modeling is acceptable.

Two-Compartment Model

More realistic for most drugs, this model recognizes that drug distribution isn't instantaneous:

Central compartment: Blood and highly perfused organs (heart, lungs, kidneys, liver)
Peripheral compartment: Slowly perfused tissues (muscle, fat, bone)
Biphasic elimination: Rapid distribution phase followed by slower elimination phase

Mathematical representation:

C(t) = A × e^(-α × t) + B × e^(-β × t)

Where:
A, B = hybrid constants
α = distribution rate constant
β = elimination rate constant
α > β (distribution faster than elimination)

Clinical significance: Most GLP-1 agonists follow two-compartment kinetics. The initial distribution phase affects early drug effects; the elimination phase determines dosing frequency.

Key Pharmacokinetic Parameters

Half-Life (t½): The Universal Clock

Half-life is the time required for drug concentration to decrease by 50%. It's constant for each drug following first-order kinetics and doesn't change with dose.

Half-Lives Elapsed	% Remaining	% Eliminated	Clinical Significance
1	50%	50%	Noticeable decrease in effect
2	25%	75%	Sub-therapeutic for most drugs
3	12.5%	87.5%	Minimal clinical effect
4	6.25%	93.75%	Near complete elimination
5	3.125%	96.875%	Considered "eliminated"

Volume of Distribution (Vd): Where Does the Drug Go?

Volume of distribution is a theoretical volume that relates drug amount in the body to plasma concentration. It doesn't represent a real physiological space but indicates drug distribution extent.

Calculation and interpretation:

Vd = Total drug in body / Plasma concentration
Vd = Dose / C₀ (after IV bolus)

Low Vd (~0.05-0.2 L/kg): Drug confined to blood
Medium Vd (~0.2-0.7 L/kg): Drug in extracellular fluid
High Vd (>0.7 L/kg): Extensive tissue distribution

GLP-1 agonists typically have low Vd due to high plasma protein binding (>99%), meaning they primarily remain in the bloodstream rather than distributing extensively into tissues.

Clearance (CL): The Body's Elimination Capacity

Clearance represents the volume of plasma completely cleared of drug per unit time. It's the most important parameter for determining maintenance dose requirements.

Key relationships:

CL = ke × Vd
CL = Dose / AUC
t½ = 0.693 × Vd / CL

Maintenance Dose Rate = CL × Css,target
Where Css,target = desired steady-state concentration

Bioavailability (F): How Much Actually Gets In?

Bioavailability is the fraction of administered dose that reaches systemic circulation unchanged. For subcutaneous injections, it accounts for incomplete absorption and local degradation.

GLP-1 agonist bioavailability:

Semaglutide SubQ: 89%
Tirzepatide SubQ: ~80%
Retatrutide SubQ: not published as of 23 October 2026 (see the note under the model parameters below); GLP3 Planner's calculator assumes 80%, borrowed from tirzepatide
Oral semaglutide: about 0.4% to 1% (Rybelsus) and 1% to 2% (Ozempic and Wegovy tablets); the tablets need an absorption enhancer, salcaprozate sodium (SNAC)

First-Order Kinetics: The Foundation of Predictable Dosing

Most drugs, including all GLP-1 agonists, follow first-order elimination kinetics. This means the rate of elimination is proportional to the amount of drug present - a constant fraction is eliminated per unit time, not a constant amount.

Mathematical Principles

Differential equation:

dC/dt = -ke × C

Solving this gives:
C(t) = C₀ × e^(-ke × t)
ln(C) = ln(C₀) - ke × t

This creates a straight line on semi-log plot
Slope = -ke/2.303 (for log₁₀ scale)

Clinical Implications

Predictable elimination: Half-life remains constant regardless of dose
Linear dose-response: Doubling the dose doubles the concentration
Accumulation predictability: Can calculate steady-state levels mathematically
Simple dose adjustments: Proportional changes in dose produce proportional changes in exposure

Steady-State: When Input Equals Output

Steady-state occurs when the rate of drug administration equals the rate of elimination. At this point, plasma concentrations fluctuate predictably between doses but average concentration remains constant.

Time to Steady-State

The 5 Half-Life Rule:

Steady-state is reached after approximately 5 half-lives, regardless of dose or dosing frequency:

After 3.3 half-lives: 90% of steady-state
After 4.3 half-lives: 95% of steady-state
After 5 half-lives: 96.9% of steady-state
After 6.6 half-lives: 99% of steady-state

GLP-1 Agonist Steady-State Timeline

Medication	Half-Life	90% Steady-State	95% Steady-State	99% Steady-State
Semaglutide	7 days	23 days	30 days	46 days
Tirzepatide	5 days	16.5 days	21.5 days	33 days
Retatrutide	6 days	20 days	26 days	40 days

Calculating Steady-State Concentrations

For repeated dosing:

Css,avg = (F × Dose) / (CL × τ)

If each dose were absorbed instantly:
Css,max = (F × Dose / Vd) / (1 - e^(-ke × τ))
Css,min = Css,max × e^(-ke × τ)

Where:
F = bioavailability
τ = dosing interval
Css = steady-state concentration
With an absorption phase the peak is lower and the trough higher than these bounds

Individual Variation: Why One Size Doesn't Fit All

Genetic Factors

Genetic polymorphisms can account for 20-95% of variability in drug response. Key factors include:

CYP450 enzymes: Polymorphisms create poor, intermediate, extensive, and ultra-rapid metabolizers
Transporter proteins: Affect drug absorption and distribution
Receptor variations: Influence drug efficacy and side effects
Clinical impact: Can alter drug clearance by 5-20 fold between individuals

Physiological Factors

Age-Related Changes:

Decreased renal clearance (~1% per year after age 40)
Reduced hepatic blood flow
Altered body composition
Increased inter-individual variability

Organ Function:

Kidney disease: Reduced renal clearance
Liver disease: Impaired metabolism
Heart failure: Altered distribution
GI disorders: Variable absorption

Body Composition Effects

Body weight and composition significantly affect pharmacokinetics:

Volume of distribution: Increases with body weight (Vd ∝ Weight^0.7)
Clearance scaling: CL ∝ Weight^0.75 (allometric scaling)
Lipophilic drugs: Greater distribution in obese patients
Hydrophilic drugs: Distribution limited to lean body mass

Clinical relevance for GLP-1 agonists: Despite weight-based PK differences, fixed dosing is used because efficacy and safety are consistent across weight ranges in clinical trials.

How GLP3 Planner Models Drug Levels

The Simulation Algorithm

GLP3 Planner's drug level calculator uses a one-compartment model with first-order absorption and elimination (the Bateman function) for semaglutide, tirzepatide, and retatrutide. It models the amount of drug in the body, in milligrams, not a blood concentration:

Core algorithm:

1. For each dose D, the amount in the body t days later is
   A(t) = F × D × ka / (ka - ke) × (e^(-ke × t) - e^(-ka × t))
   ke = ln 2 / half-life
   ka = set so that one dose peaks at the drug's time to peak
2. At each time point (every 30 minutes on the main chart),
   add up the amounts left from every earlier dose
3. Plot the total amount in the body (mg) against time
4. For the Hourly Drug Levels table only, estimate a plasma
   concentration: amount (mg) / (F × V/F in litres)

Model Parameters for Each Drug

Parameter	Semaglutide	Tirzepatide	Retatrutide
Half-life	168 hours (7 days)	120 hours (5 days)	144 hours (6 days)
ke (hr⁻¹)	0.00413	0.00578	0.00481
Time to peak (Tmax)	2 days*	1 day	1 day
Bioavailability	89%	80%	80%*
Apparent volume V/F (concentration estimate only, not the chart)	12.5 L	9.7 L (overweight or obesity; 10.3 L in type 2 diabetes)	7.4 L†

*Assumptions, not published values. Semaglutide's 2 days is the midpoint of the labels' "1 to 3 days". The labels do not say whether their times to peak were measured after one dose or at steady state; the calculator applies them to a single dose. Retatrutide's 1 day is not an assumption: in Lilly's Phase 1 trials the median time to peak was 12 to 24 hours at 1.5 to 12 mg (single doses, Coskun 2022; weekly doses, Urva 2022 appendix Table S3), and the week-12 medians at 6 and 12 mg were 24.00 and 23.92 hours (12.17 hours at 3 mg). In the Phase 1b study blood was sampled mostly 12, 24, 48 and 72 hours after a dose.^[1][6] No absolute bioavailability for retatrutide had been published as of 23 October 2026 (PubMed and Europe PMC searched, and the Coskun 2022 full text read), so the calculator borrows tirzepatide's 80%.^[1]

†The average of the six dose-group values (5.85 to 8.62 L) for the apparent volume of distribution after single doses in healthy volunteers (Coskun 2022, Table 1).^[1] The semaglutide and tirzepatide volumes are from their labels; for tirzepatide the calculator uses the Zepbound label's 9.7 L for people with overweight or obesity.^[2][3][4][5] These are total litres, not per kilogram. The chart plots an amount in milligrams and does not use them. Only the Hourly Drug Levels table does, to estimate a concentration (amount divided by F × V/F): a population average, not a measurement, and not adjusted for body weight. Half-lives: labels for semaglutide and tirzepatide, Coskun 2022 for retatrutide.

Understanding Your Plot

The Sawtooth Pattern

Each dose makes the curve rise for a day or two, to a peak at about the drug's time to peak, then fall with the drug's half-life. The regular peaks and troughs form a characteristic sawtooth pattern that becomes consistent at steady-state.

Accumulation Phase

Early doses accumulate because the drug isn't fully eliminated between doses. The accumulation factor depends on the dosing interval relative to half-life.

Steady-State Plateau

When the amount eliminated between doses equals the dose amount, concentrations plateau. The average concentration remains constant despite fluctuations.

Advanced Concepts in Pharmacokinetic Modeling

Nonlinear Pharmacokinetics

While GLP-1 agonists follow linear kinetics, understanding nonlinear kinetics helps appreciate why these drugs are easier to dose:

Saturable elimination: When enzymes become saturated (e.g., phenytoin, alcohol)
Dose-dependent half-life: Higher doses take disproportionately longer to eliminate
Unpredictable accumulation: Small dose increases can cause large concentration changes
Clinical advantage of linear kinetics: Predictable, proportional dose adjustments

Population Pharmacokinetics

Modern drug development uses population PK modeling to understand variability:

Components of variability:

Cᵢⱼ = f(Dose, Time, θᵢ) × εᵢⱼ

Where:
θᵢ = individual parameters = θₚₒₚ × e^(ηᵢ)
θₚₒₚ = population typical value
ηᵢ = inter-individual variability
εᵢⱼ = residual variability

Allometric Scaling

Body size affects PK parameters in predictable ways based on metabolic theory:

Clearance: CL = CLstd × (Weight/70)^0.75
Volume: Vd = Vd,std × (Weight/70)^1.0
Half-life: Relatively unchanged (effects cancel out)
Clinical application: Explains why many drugs use weight-based dosing

Practical Applications for GLP-1 Agonist Therapy

Optimizing Your Dosing Schedule

Key principles:

Consistency is key: Same day and time each week maintains stable levels
Missed dose management: Understanding half-life helps decide whether to take or skip
Travel adjustments: Can shift by ±2 days without significant impact
Dose escalation timing: Wait 4-5 weeks at each dose for full effect assessment

Understanding Side Effect Timing

Pharmacokinetics explains why side effects follow predictable patterns:

Peak effects: Occur 1-3 days post-injection when concentrations highest
Adaptation: Receptor desensitization reduces side effects despite stable drug levels
Dose escalation: Each increase temporarily worsens side effects until adaptation
Strategic timing: Some patients inject Friday evening to manage weekend side effects

Drug Interactions: A PK Perspective

GLP-1 agonists have minimal drug interactions due to their pharmacokinetic properties:

No CYP450 involvement: Metabolized by proteolysis, not liver enzymes
High protein binding: But displacement interactions not clinically significant
Main interaction: Delayed gastric emptying affects oral drug absorption timing
Clinical management: Take other medications 30-60 minutes before GLP-1 injection

Frequently Asked Questions

Why does it take so long to reach steady-state?

Steady-state timing depends mainly on half-life, not dose. With semaglutide's 7-day half-life, half-life arithmetic gives about 97% of steady state after 5 half-lives (35 days, 5 × 7); the Ozempic label says steady-state exposure is achieved after 4 to 5 weeks. Loading doses can achieve target levels faster but don't change the time to true steady-state.

Does body weight affect how much medication I need?

While pharmacokinetic parameters scale with body weight (clearance ∝ weight^0.75, volume ∝ weight^1.0), GLP-1 agonists use fixed dosing because clinical trials showed similar efficacy and safety across all weight ranges. The drugs' wide therapeutic window accommodates PK variability without dose adjustment.

Why do side effects improve over time despite constant drug levels?

This phenomenon, called tolerance or tachyphylaxis, occurs through receptor desensitization and physiological adaptation. GLP-1 receptors downregulate with chronic stimulation, and the GI system adapts to delayed emptying. This explains why gradual dose escalation is more tolerable than starting at high doses.

Can I split my weekly dose into multiple injections?

Theoretically, splitting doses would reduce peak-to-trough fluctuation (lower Cmax, higher Cmin) while maintaining the same average concentration. However, this isn't recommended because: 1) Clinical trials used weekly dosing, 2) The long half-life already minimizes fluctuation, 3) Multiple injections increase burden without proven benefit. The microdosing article explores this concept further.

Limitations of Pharmacokinetic Modeling

While PK modeling provides valuable insights, it's important to understand its limitations:

Model Assumptions

One absorption rate: GLP3 Planner's calculator models absorption from the injection site as a single first-order step, timed so one dose peaks at the drug's time to peak. Real absorption under the skin is more complex.
Perfect adherence: Assumes doses taken exactly as scheduled
No variability: Uses population average parameters, not individual values
Linear kinetics: Assumes no saturation at any dose level
Single compartment: Simplification of multi-compartment reality

Clinical Correlation

Important: Plasma concentration doesn't directly correlate with clinical effect. Factors like receptor sensitivity, tolerance development, and individual response variability mean two people with identical drug levels may experience different effects. PK modeling helps understand drug behavior but doesn't predict individual clinical outcomes.

When Models Matter Most

PK modeling is most useful for:

Understanding accumulation during dose escalation
Predicting impact of missed doses
Planning medication switches or discontinuation
Educational understanding of drug behavior
Research and drug development

Clinical Application Summary

Here's what all this means in practice for semaglutide, tirzepatide, and retatrutide therapy:

Be patient - it takes about 4 weeks (tirzepatide, and by estimate retatrutide) to 4-5 weeks (semaglutide) to reach steady-state
Consistency in dosing time maintains stable levels
Side effects often improve despite constant drug levels
Individual variation is normal and expected
The long half-life provides flexibility for missed doses
Use GLP3 Planner's calculator to visualize your drug levels and see these PK principles in action

Always work with your healthcare provider to optimize your individual treatment plan based on your response, not just pharmacokinetic predictions.

References

Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
Novo Nordisk. Wegovy (semaglutide) injection prescribing information, section 12.3. DailyMed. DailyMed
Novo Nordisk. Ozempic (semaglutide) injection prescribing information, section 12.3. DailyMed. DailyMed
Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information, section 12.3. DailyMed. DailyMed
Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information, section 12.3. DailyMed. DailyMed
Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. Supplementary appendix, Table S3 (time to peak) and protocol (sampling schedule). PubMed · Appendix

How GLP3 Planner's calculators use these values, and which ones are assumptions, is set out in the PK methodology.

Medical Disclaimer

This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or recommendations. Modelled drug levels are population-average estimates and do not predict individual drug levels. Always consult your doctor before starting, adjusting, or stopping any medication.